Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / Proteomics Biomarker Development Laboratory

Proteomics Biomarker Development Laboratory


No lead investigator defined.

No coordinating investigator defined.

No involved investigator sites defined.


The Biomarker Development Laboratory is focused on the application of a proteomic approach for the development of cancer biomarkers. The laboratory will apply technologies for protein analysis to the detection and identification of proteins secreted by tumor cells and protein antigens that induce a humoral response in tumors. The initial targeted tumor types for the identification of potential biomarker proteins are: Colon, esophagus, ovary, lung, breast and liver. The proposed studies will make heavy utilization of two-dimensional (2-D) protein analysis, of protein identification technologies and of database capabilities that have been developed by the applicant group. The objectives of this research are to 1. Identify tumor antigens that induce a humoral response; 2. Identify tumor secreted proteins and developa database; 3. Preliminarily validate the potential utilityof markers for early cancer detection. Sixty ml of bloodwill be obtained from healthy normals, and from small cell lung cancer, hepatoma, esophageal, and breast cancerpatients, and from ovarian, colon, and non-small cell lungcancer patients prior to surgical resection and six toten weeks after resection. Demographic data, sera and DNA will be used in 2-D protein analysis to identify newor altered proteins. The initial validation will be the assay of the presence or absence of a given protein in alarge sample cohort from the samples collected from thesepatients. There is no specified age range, although the diseases under study do not occur in children. No subjectswill be excluded on the basis of race or gender. Womenof child bearing age will be studied. Linkable demographicdata will be held separately from the bar-coded serum orDNA samples. Serum and DNA sample will be identifiableonly by subject identification number. Full written informed consent will be obtained from patients.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.